IMMUNOLOGY2026™ Conference Recordings For Attendees-The antigen-specific immunotherapy, AKS-107, selectively depletes anti-insulin B lymphocytes in the pancreas and reduces insulitis in T1D-prone mice

The antigen-specific immunotherapy, AKS-107, selectively depletes anti-insulin B lymphocytes in the pancreas and reduces insulitis in T1D-prone mice

Back to course

Video Transcription

Video Summary

The talk described AKS107, an antigen-specific immunotherapy designed to selectively deplete anti-insulin B cells in type 1 diabetes while sparing other B cells. Using VH125 NOD mice, the researchers showed that AKS107 reduced anti-insulin B-cell populations in the spleen, pancreatic lymph nodes, and pancreas. Depletion was strongest in the spleen and pancreatic lymph nodes, and improved in the pancreas with longer dosing. Importantly, overall non–insulin-specific B cells were largely unaffected, suggesting selective targeting. In wild-type NOD mice, longer AKS107 treatment also reduced insulitis, the immune-cell infiltration that damages pancreatic islets. The study supports AKS107 as a preclinical antigen-specific therapy that may more safely reduce autoimmune activity than broad immunosuppression, though translation to humans and long-term durability still need further study.

Meta Tag

Date April 16, 2026 8:45 AM - 9:00 AM

Room 156

Session Targeting B Cells and Innate Immune Functions in Autoimmunity

Speaker Tyler Jenkins

Track Therapeutic Approaches to Autoimmunity (THER)

Year 2026

Keywords

AKS107

type 1 diabetes

anti-insulin B cells

antigen-specific immunotherapy

insulitis

April 16, 2026 8:45 AM - 9:00 AM

156

Targeting B Cells and Innate Immune Functions in Autoimmunity

Tyler Jenkins

Therapeutic Approaches to Autoimmunity (THER)

2026